The Cancer Degradome: Proteases and Cancer Biology by Dylan EdwardsThe Cancer Degradome: Proteases and Cancer Biology by Dylan Edwards

The Cancer Degradome: Proteases and Cancer Biology

EditorDylan Edwards, Gunilla Hoyer-Hansen, Francesco Blasi

Hardcover | September 19, 2008

Pricing and Purchase Info

$283.91 online 
$324.95 list price save 12%
Earn 1,420 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


This book will aim to cover recent knowledge of the composition of the Degradome, how it can be studied using modern approaches such as transcriptomics and mass spectrometry; how gene knockout mice have improved our knowledge of the roles of proteases in cancer; how their activity can be imaged both in vitro and in vivo; the links that have emerged between proteolysis and cell signalling; how the degradome can be a useful source of diagnostic and prognostic markers; and finally new approaches to targeting proteolysis for therapy.
Title:The Cancer Degradome: Proteases and Cancer BiologyFormat:HardcoverDimensions:950 pagesPublished:September 19, 2008Publisher:Springer New YorkLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0387690565

ISBN - 13:9780387690568

Look for similar items by category:


Table of Contents

Section 1: The Degradome and its analysisChapter 1: Protease Genomics and the Cancer DegradomeXose S. Puente, Gonzalo R Ordonez & Carlos López-OtínChapter 2: The CLIP-CHIP: A focused oligonucleotide microarray platform for transcriptone analysis for the complete human and murine cancer degradomes.Rheinhild Kappelhoff, Claire H.Wilson, & Christopher M. OverallChapter 3: The Hu/Mu ProtIn chip: A custom dual-species Oligonucleotide Microarray for profiling degradome gene expression in tumours and their microenvironmentDonald R.Scwartz, Kamiar Moin, Ekkehard Weber & Bonnie F SloaneChapter 4: Quantitative Real-Time PCR analysis of degradome gene expressionCaroline J Pennington, Robert K. Nuttall, Clara Sampieri -Ramirez, , Matthew Wallard, Simon Pilgrim & Dylan R. EdwardsChapter 5: Identification of protease substrates by mass spectrometry approaches.Mari Enoksson,Wenhong Zhu & Guy Salvesen Chapter 6: Identification of protease substrates by mass spectrometry approaches - 2.Anna Prudova, Ulrich auf dem Keller & Christopher M. OverallChapter 7: Activity based imaging and biochemical profiling tools for analysis of the cancer degradome.Vincent Dive, Margot Paulick, J.Oliver McIntyre, Lynn M. Matrisan & Matthew Bogyo.Chapter 8: Images of cleavageKamiar Moin,Mansoureh Sameni, Christopher Jedeszko, Quanwen Li, Mary B. Olive, Raymond R. Mattingly & Bonnie F. SloaneSection 2: Insights into Protease functionChapter 9: Proteolytic pathways: Intersecting cascades in cancer developmentNesrine I. Affara & Lisa M, CoussensChapter 10: Physiological functions of plasminogen activation: Effects of gene deficiences in humans and miceThomas H. Bugge Chapter 11: The plasminogen activation system in tissue remodelling and cancer invasionKasper Almholt, Anna Juncker-Jensen, Kirsty Anne Green, Helene Solberg, Leif Roge Lund & John RømerChapter 12: The urokinase plasminogen activator receptor as a target for cancer therapySilvia D'Alessio & Francesco Blasi Chapter 13: The endocytic collagen receptor uPARAP/Endo 180 in cancer invasion and tissue remodellingThore Hillig, Lars H. Engelholm & Niels BehrendtChapter 14: Physiological and pathological functions of type II transmembrane serine proteinases:Lessons from transgenic mouse models and human disease-associated mutations.Karin List & Thomas BuggeChapter 15: Analysis of cysteine cathepsin knockout mice in cancer modelsThomas Reinheckel, Vasilena Gocheva, Christoph Peters & Johanna A. JoyceChapter 16: In vitro and in vivo models of angiogenesis to dissect MMP functions.Sarah Berndt, Françoise Bruyère, Maud Jost & Agnès NoëlChapter 17: The surface transplantation model to study the tumour-host interface Maud Jost, Silvia Vosseler, Silvia Blacher, Norbert E. Fusenig, Margareta Mueller & Agnes NoelChapter 18: Unravelling the roles of proteases in cell migration in vitro and in vivoJelena Gavrilovic & Xanthe ScottChapter 19: New insights into MMP function in adipogenesisKumari L Andarawewal & Marie-Christine RiolChapter 20: TIMPs:Extracellular Modifiers in Cancer DevelopmentAditya Murty,William Cruz-Munoz & Rama KhokhaSection 3: The interface between Proteolysis and Cell SignallingChapter 21: Invadopodia: Interface for InvasionSusette C Mueller, Vira V. Artym & Thomas KellyChapter 22: uPAR and proteases in mobilization of hematopoietic stem cellsPia Ragno & Francesco BlasiChapter 23: The urokinase receptor (uPAR) and integrins constitute a cell migration signalosomeBernard DegryseChapter 24: Measuring uPAR dynamics in live cellsMoreno Zamai, Gabriele Malengo & Valeria R. CaiolfaChapter 25: Janus-faced effects of broad-spectrum and specific MMP inhibition on metastasisCharlotte Kopitz & Achim KrugerChapter 26: Cytokine Substrates: MMP regulation of inflammatory signalling moleculesJennifer H. Cox & Christopher M. OverallChapter 27: Matrix metalloproteinases as key regulators of tumour:bone interactionConor C. Lynch & Lynn M. MatrisanSection 4: The degradome as source of cancer diagnostic and prognostic markersChapter 28: The plasminogen activation system as a source of prognostic markers in cancerIb Jarle Christensen, Helle Pappot & Gunilla Hoyer-HansenChapter 29: Cysteine cathepsins and cystatins as cancer biomarkersTamara T. Lah, Natasa Obermaja, Maria Beatriz Duran Alonso & Janko KosChapter 30: Novel degradome markers in breast cancerCaroline J. Pennington, Simon Pilgrim, Paul N Span Fred C. Sweep & Dylan R. EdwardsChapter 31: Meta-analysis of gene expression microarray data: Degradome genes in healthy and cancer tissuesKristiina Iljin, Sami Kilpinen, Johanna Ivaska & Olli KallioniemiChapter 32: Degradome gene polymorphismsRoss Laxton & Shu YeChapter 33: TIMP-1 as a prognostic marker in colorectal cancerCamilla Frederiksen, Anne Fog Lomholt,Hans Jorgen Nielsen & Nils BrunnerChapter 34: Structure and inhibition of the urokinase-type plasminiogen activator receptor (uPAR)Benedikte Jacobsen, Magnus Kjaergaard, Henrik Gardsvoll & Michael PlougChapter 35: Engineered antagonists of uPA and PAI-1M. Patrizia Stoppelli, Lisbeth M, Andersen, Giuseppina Votta & Peter A. AndreasenChapter 36: MMP inhibitor clinical trials - the past present and futureBarbara FingletonChapter 37: Tailoring TIMPs for selective metalloproteinase inhibitionHideaki Nagase & Gillian MurphyChapter 38: Third Generation MMP Inhibitors: Recent advances in the development of highly selective inhibitorsAthanasios Yiotakis & Vincent DiveChapter 39: Protease activated delivery and Imaging systemsGregg FieldsChapter 40: Development of tumour selective and endoprotease-activated anticancer therapeuticsJason H. Gill & Paul M. LoadmanChapter 41: Targeting Degradome genes via engineered Viral VectorsRisto Ala-aho, Andrew H. Baker & Veli-Matti Kahari